{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:26:29Z","timestamp":1793805989706,"version":"4.6.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,3,18]],"date-time":"2010-03-18T00:00:00Z","timestamp":1268870400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/1471-2334-10-72","type":"journal-article","created":{"date-parts":[[2010,3,18]],"date-time":"2010-03-18T19:14:12Z","timestamp":1268939652000},"source":"Crossref","is-referenced-by-count":32,"title":["Comparative in vitro activity of Meropenem, Imipenem and Piperacillin\/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study"],"prefix":"10.1186","volume":"10","author":[{"given":"Marie-Laure","family":"Joly-Guillou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Kempf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Didier","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Chomarat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Maugein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudette","family":"Muller-Serieys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheline","family":"Roussel-Delvallez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,3,18]]},"reference":[{"key":"1052_CR1","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","volume":"67","author":"GG Zhanel","year":"2007","unstructured":"Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA: Comparative review of the carbapenems. Drugs. 2007, 67: 1027-1052. 10.2165\/00003495-200767070-00006.","journal-title":"Drugs"},{"key":"1052_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.diagmicrobio.2005.10.006","volume":"53","author":"RN Jones","year":"2005","unstructured":"Jones RN, Mendes C, Turner PJ, Masterton R: An overview of the meropenem yearly susceptibility test information collection (MYSTIC) Program: 1997-2004. Diagn Microbiol Infect Dis. 2005, 53: 247-256. 10.1016\/j.diagmicrobio.2005.10.006.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1052_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.diagmicrobio.2005.10.002","volume":"53","author":"S Unal","year":"2005","unstructured":"Unal S, Garcia-Rodriguez JA: Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. Isolated in the MYSTIC Program, 2002-2004. Diagn Microbiol Infect Dis. 2005, 53: 265-271. 10.1016\/j.diagmicrobio.2005.10.002.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1052_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijantimicag.2005.09.011","volume":"27","author":"RG Masterton","year":"2006","unstructured":"Masterton RG, Turner PJ: Trends in antimicrobial susceptibility in UK centres: the MYSTIC programme (1997-2002). Int J Antimicrob Agents. 2006, 27: 69-72. 10.1016\/j.ijantimicag.2005.09.011.","journal-title":"Int J Antimicrob Agents"},{"key":"1052_CR5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.diagmicrobio.2006.07.015","volume":"56","author":"PJ Turner","year":"2006","unstructured":"Turner PJ: Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program. Diagn Microbiol Infect Dis. 2006, 56: 341-344. 10.1016\/j.diagmicrobio.2006.07.015.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1052_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.diagmicrobio.2007.05.009","volume":"59","author":"PR Rhomberg","year":"2006","unstructured":"Rhomberg PR, Deshpande LM, Kirby JT, Jones RN: Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program. Diagn Microbiol Infect Dis. 2006, 59: 425-432. 10.1016\/j.diagmicrobio.2007.05.009.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1052_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.diagmicrobio.2006.07.009","volume":"57","author":"PR Rhomberg","year":"2007","unstructured":"Rhomberg PR, Jones RN: Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the Unites States component (2005). Diagn Microbiol Infect Dis. 2007, 57: 207-215. 10.1016\/j.diagmicrobio.2006.07.009.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1052_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.diagmicrobio.2008.01.017","volume":"61","author":"RN Jones","year":"2008","unstructured":"Jones RN, Kirby JT, Rhomberg PR: Comparative activity of meropenem in US Medical Centers (2007): initiating the 2nd decade MYSTIC Program surveillance. Diagn Microbiol Infect Dis. 2008, 61: 203-213. 10.1016\/j.diagmicrobio.2008.01.017.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1052_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.diagmicrobio.2008.04.012","volume":"62","author":"GG Zhanel","year":"2008","unstructured":"Zhanel GG, DeCorby M, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA, Lagac\u00e9-Wiens P, Walkty A, Mulvey MR, Hoban DJ: Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005\/2006. Diagn Microbiol Infect Dis. 2008, 62: 67-80. 10.1016\/j.diagmicrobio.2008.04.012.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1052_CR10","first-page":"P612","volume-title":"18th European Congress of Clinical Microbiology and Infectious Diseases Barcelona","author":"ML Joly-Guillou","year":"2008","unstructured":"Joly-Guillou ML, Cavallo JD, Chomarat M, Dubreuil L, Maugein J, Muller-Serieys C, Roussel-Delvallez M: Comparative activity of meropenem, imipenem and piperacillin\/tazobactam against 1118 bacteria involved in hospital infections: a French multicentre study [Abstract]. 18th European Congress of Clinical Microbiology and Infectious Diseases Barcelona. 2008, P612-"},{"key":"1052_CR11","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0924-8579(03)00021-9","volume":"21","author":"Members of the SFM Antibiogram Committee","year":"2006","unstructured":"Members of the SFM Antibiogram Committee: Comit\u00e9 de l'Antibiogramme de la Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie, Report 2003. Int J Antimicrob Agents. 2006, 21: 364-391. 10.1016\/S0924-8579(03)00021-9.","journal-title":"Int J Antimicrob Agents"},{"key":"1052_CR12","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1469-0691.2006.01454.x","volume":"12","author":"G Kahlmeter","year":"2006","unstructured":"Kahlmeter G, Brown DF, Goldstein FW, MacGowan AP, Moutons JW, Odenholt I, Rodloff A, Soussy CJ, Steinbakk M, Soriano F, Stetsiouk O: European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing. Clin Microbiol Infect. 2006, 12: 501-503. 10.1111\/j.1469-0691.2006.01454.x.","journal-title":"Clin Microbiol Infect"},{"key":"1052_CR13","volume-title":"100 recommandations pour la surveillance et la pr\u00e9vention des infections nosocomiales","author":"Comit\u00e9 technique national des infections nosocomiales","year":"1999","unstructured":"Comit\u00e9 technique national des infections nosocomiales: 100 recommandations pour la surveillance et la pr\u00e9vention des infections nosocomiales. 1999, Minist\u00e8re de l'Emploi et de la Solidarit\u00e9 Secr\u00e9tariat d'Etat \u00e0 la Sant\u00e9 et \u00e0 l'action sociale"},{"key":"1052_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0732-8893(93)90101-C","volume":"17","author":"RN Jones","year":"1993","unstructured":"Jones RN, Erwin ME, Hager HL, Hohl PE: Interlaboratory variations of fluoroquinolone susceptibility testing. An international study to validate the quality of microbiology results reported during the fleroxacin clinical trials. Diagn Microbiol Infect Dis. 1993, 17: 225-232. 10.1016\/0732-8893(93)90101-C.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1052_CR15","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/jac\/dkh060","volume":"53","author":"RN Jones","year":"2004","unstructured":"Jones RN, Gordon KA, Biedenbach DJ: Comparisons of the in vitro susceptibility testing results for garenoxacin using six different national methods: report from the garenoxacin international bridging study. J Antimicrob Chemother. 2004, 53: 258-265. 10.1093\/jac\/dkh060.","journal-title":"J Antimicrob Chemother"},{"key":"1052_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.diagmicrobio.2007.09.006","volume":"60","author":"PJ Turner","year":"2008","unstructured":"Turner PJ: Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn Microbiol Infect Dis. 2008, 60: 185-192. 10.1016\/j.diagmicrobio.2007.09.006.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1052_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.diagmicrobio.2005.10.001","volume":"53","author":"H Goossens","year":"2005","unstructured":"Goossens H, Grabein B: Prevalence and antimicrobial susceptibility data for extended-spectrum \u03b2-lactamase- and Amp C-producing enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004). Diagn Microbiol Infect Dis. 2005, 53: 257-264. 10.1016\/j.diagmicrobio.2005.10.001.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1052_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkn241","volume":"62","author":"PM Hawkey","year":"2008","unstructured":"Hawkey PM: The growing burden of antimicrobial resistance. J Antimicrob Chemother. 2008, 62: 1-9. 10.1093\/jac\/dkn241.","journal-title":"J Antimicrob Chemother"},{"key":"1052_CR19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/jac\/dkn184","volume":"62","author":"JA Patzer","year":"2008","unstructured":"Patzer JA, Dzierzanowska D, Turner PJ: Trends in antimicrobial susceptibility of Gram negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997-2007). J Antimicrob Chemother. 2008, 62: 369-375. 10.1093\/jac\/dkn184.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"1052_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1469-0691.2007.01867.x","volume":"14","author":"GM Rossolini","year":"2008","unstructured":"Rossolini GM, D'Andrea MM, Mugnaioli C: The spread of CTX-M-type extended-spectrum beta-lactamases. Clin Microbiol Infect. 2008, 14 (Suppl 1): 33-41. 10.1111\/j.1469-0691.2007.01867.x.","journal-title":"Clin Microbiol Infect"},{"key":"1052_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ijantimicag.2006.08.014","volume":"28","author":"JR Hern\u00e1ndez","year":"2006","unstructured":"Hern\u00e1ndez JR, Velasco C, Romero L, Marti\u00ecnez-Marti\u00ecnez L, Pascual A: Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain. Int J Antimicrob Agents. 2006, 28: 457-459. 10.1016\/j.ijantimicag.2006.08.014.","journal-title":"Int J Antimicrob Agents"},{"key":"1052_CR22","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2165\/00003495-200868060-00006","volume":"68","author":"CM Baldwin","year":"2008","unstructured":"Baldwin CM, Lyseng-Williamson KA, Keam SJ: Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs. 2008, 68: 803-838. 10.2165\/00003495-200868060-00006.","journal-title":"Drugs"},{"key":"1052_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/jac\/dkg028","volume":"51","author":"G Kahlmete","year":"2003","unstructured":"Kahlmete G: An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO-SENS Project. J Antimicrob Chemother. 2003, 51: 69-76. 10.1093\/jac\/dkg028.","journal-title":"J Antimicrob Chemother"},{"key":"1052_CR24","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/jac\/dkh128","volume":"53","author":"AC Nicodemo","year":"2004","unstructured":"Nicodemo AC, Araujo MR, Ruiz AS, Gales AC: In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, Etest and agar dilution methods. J Antimicrob Chemother. 2004, 53: 604-608. 10.1093\/jac\/dkh128.","journal-title":"J Antimicrob Chemother"},{"key":"1052_CR25","first-page":"107","volume":"60","author":"H Muramatsu","year":"2007","unstructured":"Muramatsu H, Ishikawa J, Nagura O, Horii T: Comparison of susceptibilities for fosfomycin determined by various methods in clinical isolates in 2003-2004. Jpn J Antibiot. 2007, 60: 107-124.","journal-title":"Jpn J Antibiot"},{"key":"1052_CR26","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1128\/AAC.47.11.3430-3434.2003","volume":"47","author":"JA V\u00e1zquez","year":"2003","unstructured":"V\u00e1zquez JA, Arreaza L, Block C, Ehrhard I, Gray SJ, Heuberger S, Hoffmann S, Kriz P, Nicolas P, Olcen P, Skoczynska A, Spanjaard L, Stefanelli P, Taha MK, Tzanakaki G: Interlaboratory comparison of agar dilution and Etest methods for determining the MICs of antibiotics used in management of Neisseria meningitidis infections. Antimicrob Agents Chemother. 2003, 47: 3430-3434. 10.1128\/AAC.47.11.3430-3434.2003.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-10-72\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-10-72.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-10-72","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-10-72.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T07:29:56Z","timestamp":1548142196000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-10-72"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,18]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["1052"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-10-72","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,18]]},"article-number":"72"}}